[
    [
        {
            "time": "",
            "original_text": "贝达药业(300558.SZ)首次公开发行境外上市外资股（H股）获得中国证监会批复",
            "features": {
                "keywords": [
                    "贝达药业",
                    "H股",
                    "证监会",
                    "批复"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)首次公开发行境外上市外资股（H股）获得中国证监会批复",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药行业2020年年报及2021年一季报总结：Q1业绩复苏回暖 看好CXO、疫苗、创新器械和服务等高景气板块",
            "features": {
                "keywords": [
                    "医药行业",
                    "年报",
                    "一季报",
                    "CXO",
                    "疫苗",
                    "创新器械",
                    "服务"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药行业2020年年报及2021年一季报总结：Q1业绩复苏回暖 看好CXO、疫苗、创新器械和服务等高景气板块",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "贝达药业大跌7.05%，成交额3.32亿元 连续下跌",
            "features": {
                "keywords": [
                    "贝达药业",
                    "大跌",
                    "连续下跌"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业大跌7.05%，成交额3.32亿元 连续下跌",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        }
    ]
]